Skip to main content
Top
Published in: Esophagus 3/2023

20-01-2023 | Esophageal Cancer | Original Article

Old age and intense chemotherapy exacerbate negative prognostic impact of postoperative complication on survival in patients with esophageal cancer who received neoadjuvant therapy: a nationwide study from 85 Japanese esophageal centers

Authors: Satoru Matsuda, Yuko Kitagawa, Jun Okui, Akihiko Okamura, Hirofumi Kawakubo, Ryo Takemura, Manabu Muto, Yoshihiro Kakeji, Hiroya Takeuchi, Masayuki Watanabe, Yuichiro Doki

Published in: Esophagus | Issue 3/2023

Login to get access

Abstract

Background

The prognostic impact of docetaxel, cisplatin, and 5-FU (DCF) reported in JCOG1109 was successfully validated using real-world data in patients < 75 years old. However, DCF was not reported to be beneficial in elderly patients with a relatively higher postoperative complication incidence. This study aimed to clarify the impact of postoperative complications on the prognosis of ESCC and the difference in the magnitude of the impact by age and regimen.

Methods

Patients with esophageal squamous cell carcinoma (ESCC) who underwent subtotal esophagectomy at 85 authorized institutes were retrospectively reviewed from 2010 to 2015. The prognostic impact of postoperative anastomotic leakage (AL) and pneumonia on survival was evaluated. The prognostic value of the postoperative complications was assessed by stratifying patients according to age and neoadjuvant chemotherapy regimen.

Results

Patients with AL, pneumonia, and infectious complications (ICs: a combination of pneumonia and AL) showed significantly worse overall survival (OS). IC served as a negative prognostic factor of OS and recurrence-free survival, and its negative prognostic impact was more evident in patients aged > 75 years. When the patients were further stratified by chemotherapeutic regimens, using the CF/IC(−) group as a reference, the DCF/IC (+) group showed significantly shorter OS in patients aged > 75 years with a hazard ratio (HR) of 2.551. The HR of the CF/IC (+) group was 1.503.

Conclusions

The negative impact of postoperative complications on survival was confirmed in this nationwide study. Furthermore, its magnitude was higher in elderly patients who received triplet chemotherapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Watanabe M, Otake R, Kozuki R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today. 2020;50:12–20.CrossRefPubMed Watanabe M, Otake R, Kozuki R, et al. Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surg Today. 2020;50:12–20.CrossRefPubMed
2.
go back to reference Matsuda S, Takeuchi H, Kawakubo H, et al. Current advancement in multidisciplinary treatment for resectable cStage II/III esophageal squamous cell carcinoma in Japan. Ann Thorac Cardiovasc Surg. 2016;22:275–83.CrossRefPubMedPubMedCentral Matsuda S, Takeuchi H, Kawakubo H, et al. Current advancement in multidisciplinary treatment for resectable cStage II/III esophageal squamous cell carcinoma in Japan. Ann Thorac Cardiovasc Surg. 2016;22:275–83.CrossRefPubMedPubMedCentral
3.
go back to reference Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16:1–24.CrossRefPubMed Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus. 2019;16:1–24.CrossRefPubMed
4.
go back to reference Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: Part 2. Esophagus. 2019;16:25–43.CrossRefPubMed Kitagawa Y, Uno T, Oyama T, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: Part 2. Esophagus. 2019;16:25–43.CrossRefPubMed
5.
go back to reference van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRefPubMed van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.CrossRefPubMed
6.
go back to reference Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384:1191–203.CrossRefPubMed Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384:1191–203.CrossRefPubMed
7.
go back to reference Kato K, Ito Y, Daiko H, et al. A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. J Clin Oncol. 2022;40:238–238.CrossRef Kato K, Ito Y, Daiko H, et al. A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. J Clin Oncol. 2022;40:238–238.CrossRef
8.
9.
go back to reference Kakeji Y, Takahashi A, Hasegawa H, et al. Surgical outcomes in gastroenterological surgery in Japan: report of the national clinical database 2011–2018. Ann Gastroenterol Surg. 2020;4:250–74.CrossRefPubMedPubMedCentral Kakeji Y, Takahashi A, Hasegawa H, et al. Surgical outcomes in gastroenterological surgery in Japan: report of the national clinical database 2011–2018. Ann Gastroenterol Surg. 2020;4:250–74.CrossRefPubMedPubMedCentral
10.
go back to reference Ozawa S, Koyanagi K, Ninomiya Y, et al. Postoperative complications of minimally invasive esophagectomy for esophageal cancer. Ann Gastroenterol Surg. 2020;4:126–34.CrossRefPubMedPubMedCentral Ozawa S, Koyanagi K, Ninomiya Y, et al. Postoperative complications of minimally invasive esophagectomy for esophageal cancer. Ann Gastroenterol Surg. 2020;4:126–34.CrossRefPubMedPubMedCentral
11.
go back to reference Kinugasa S, Tachibana M, Yoshimura H, et al. Postoperative pulmonary complications are associated with worse short- and long-term outcomes after extended esophagectomy. J Surg Oncol. 2004;88:71–7.CrossRefPubMed Kinugasa S, Tachibana M, Yoshimura H, et al. Postoperative pulmonary complications are associated with worse short- and long-term outcomes after extended esophagectomy. J Surg Oncol. 2004;88:71–7.CrossRefPubMed
12.
go back to reference Rutegård M, Lagergren P, Rouvelas I, et al. Surgical complications and long-term survival after esophagectomy for cancer in a nationwide Swedish cohort study. Eur J Surg Oncol. 2012;38:555–61.CrossRefPubMed Rutegård M, Lagergren P, Rouvelas I, et al. Surgical complications and long-term survival after esophagectomy for cancer in a nationwide Swedish cohort study. Eur J Surg Oncol. 2012;38:555–61.CrossRefPubMed
13.
go back to reference Booka E, Takeuchi H, Nishi T, et al. The impact of postoperative complications on survivals after esophagectomy for esophageal cancer. Medicine. 2015;94: e1369.CrossRefPubMedPubMedCentral Booka E, Takeuchi H, Nishi T, et al. The impact of postoperative complications on survivals after esophagectomy for esophageal cancer. Medicine. 2015;94: e1369.CrossRefPubMedPubMedCentral
14.
go back to reference Kataoka K, Takeuchi H, Mizusawa J, et al. Prognostic impact of postoperative morbidity after esophagectomy for esophageal cancer: exploratory analysis of JCOG9907. Ann Surg. 2017;265:1152–7.CrossRefPubMed Kataoka K, Takeuchi H, Mizusawa J, et al. Prognostic impact of postoperative morbidity after esophagectomy for esophageal cancer: exploratory analysis of JCOG9907. Ann Surg. 2017;265:1152–7.CrossRefPubMed
15.
go back to reference Fransen LFC, Berkelmans GHK, Asti E, et al. The effect of postoperative complications after minimally invasive esophagectomy on long-term survival: an international multicenter cohort study. Ann Surg. 2021;274:e1129–37.CrossRefPubMed Fransen LFC, Berkelmans GHK, Asti E, et al. The effect of postoperative complications after minimally invasive esophagectomy on long-term survival: an international multicenter cohort study. Ann Surg. 2021;274:e1129–37.CrossRefPubMed
16.
go back to reference Shimada H, Fukagawa T, Haga Y, et al. Does postoperative morbidity worsen the oncological outcome after radical surgery for gastrointestinal cancers? A systematic review of the literature. Ann Gastroenterol Surg. 2017;1:11–23.CrossRefPubMedPubMedCentral Shimada H, Fukagawa T, Haga Y, et al. Does postoperative morbidity worsen the oncological outcome after radical surgery for gastrointestinal cancers? A systematic review of the literature. Ann Gastroenterol Surg. 2017;1:11–23.CrossRefPubMedPubMedCentral
17.
go back to reference Li KK, Wang YJ, Liu XH, et al. The effect of postoperative complications on survival of patients after minimally invasive esophagectomy for esophageal cancer. Surg Endosc. 2017;31:3475–82.CrossRefPubMed Li KK, Wang YJ, Liu XH, et al. The effect of postoperative complications on survival of patients after minimally invasive esophagectomy for esophageal cancer. Surg Endosc. 2017;31:3475–82.CrossRefPubMed
18.
go back to reference Takeuchi M, Kawakubo H, Mayanagi S, et al. Influence of neoadjuvant therapy on poor long-term outcomes of postoperative complications in patients with esophageal squamous cell carcinoma: a retrospective cohort study. Ann Surg Oncol. 2019;26:2081–9.CrossRefPubMed Takeuchi M, Kawakubo H, Mayanagi S, et al. Influence of neoadjuvant therapy on poor long-term outcomes of postoperative complications in patients with esophageal squamous cell carcinoma: a retrospective cohort study. Ann Surg Oncol. 2019;26:2081–9.CrossRefPubMed
19.
go back to reference Sano J, Matsuda S, Kawakubo H, et al. Exposure to a postoperative hypercoagulable state predicts poor prognosis after transthoracic esophagectomy in patients with esophageal cancer. Ann Surg Oncol. 2022;29:4488–97. CrossRef Sano J, Matsuda S, Kawakubo H, et al. Exposure to a postoperative hypercoagulable state predicts poor prognosis after transthoracic esophagectomy in patients with esophageal cancer. Ann Surg Oncol. 2022;29:4488–97. CrossRef
20.
go back to reference Matsuda S, Takeuchi H, Kawakubo H, et al. Correlation between intense postoperative inflammatory response and survival of esophageal cancer patients who underwent transthoracic esophagectomy. Ann Surg Oncol. 2015;22:4453–60.CrossRefPubMed Matsuda S, Takeuchi H, Kawakubo H, et al. Correlation between intense postoperative inflammatory response and survival of esophageal cancer patients who underwent transthoracic esophagectomy. Ann Surg Oncol. 2015;22:4453–60.CrossRefPubMed
21.
go back to reference Okamura A, Yamashita K, Kozuki R, et al. Inflammatory response and recurrence after minimally invasive esophagectomy. Langenbecks Arch Surg. 2019;404:761–9.CrossRefPubMed Okamura A, Yamashita K, Kozuki R, et al. Inflammatory response and recurrence after minimally invasive esophagectomy. Langenbecks Arch Surg. 2019;404:761–9.CrossRefPubMed
23.
go back to reference Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefPubMedPubMedCentral
24.
go back to reference Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6:119–30.CrossRefPubMedPubMedCentral Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6:119–30.CrossRefPubMedPubMedCentral
25.
go back to reference Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.CrossRefPubMed Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.CrossRefPubMed
26.
go back to reference Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57.CrossRefPubMed Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393:1948–57.CrossRefPubMed
27.
go back to reference Booka E, Haneda R, Ishii K, et al. The negative impact of preoperative chemotherapy on survival after esophagectomy for vulnerable elderly patients with esophageal cancer. Ann Surg Oncol. 2021;28:1786–95.CrossRefPubMed Booka E, Haneda R, Ishii K, et al. The negative impact of preoperative chemotherapy on survival after esophagectomy for vulnerable elderly patients with esophageal cancer. Ann Surg Oncol. 2021;28:1786–95.CrossRefPubMed
29.
go back to reference Miyamoto M, Kobayashi Y, Miyata E, et al. Residual recurrent nerve paralysis after esophagectomy is associated with preoperative lower serum albumin. Dysphagia. 2017;32:520–5.CrossRefPubMed Miyamoto M, Kobayashi Y, Miyata E, et al. Residual recurrent nerve paralysis after esophagectomy is associated with preoperative lower serum albumin. Dysphagia. 2017;32:520–5.CrossRefPubMed
30.
go back to reference Janssen T, Fransen LFC, Heesakkers F, et al. Effect of a multimodal prehabilitation program on postoperative recovery and morbidity in patients undergoing a totally minimally invasive esophagectomy. Dis Esophagus. 2022;35:doab082. CrossRefPubMed Janssen T, Fransen LFC, Heesakkers F, et al. Effect of a multimodal prehabilitation program on postoperative recovery and morbidity in patients undergoing a totally minimally invasive esophagectomy. Dis Esophagus. 2022;35:doab082. CrossRefPubMed
31.
go back to reference Felip E, Ardizzoni A, Ciuleanu T, et al. CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. Eur J Cancer. 2020;127:160–72.CrossRefPubMed Felip E, Ardizzoni A, Ciuleanu T, et al. CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. Eur J Cancer. 2020;127:160–72.CrossRefPubMed
32.
go back to reference Dudnik E, Moskovitz M, Daher S, et al. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data. Lung Cancer. 2018;126:217–23.CrossRefPubMed Dudnik E, Moskovitz M, Daher S, et al. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: the real-life data. Lung Cancer. 2018;126:217–23.CrossRefPubMed
Metadata
Title
Old age and intense chemotherapy exacerbate negative prognostic impact of postoperative complication on survival in patients with esophageal cancer who received neoadjuvant therapy: a nationwide study from 85 Japanese esophageal centers
Authors
Satoru Matsuda
Yuko Kitagawa
Jun Okui
Akihiko Okamura
Hirofumi Kawakubo
Ryo Takemura
Manabu Muto
Yoshihiro Kakeji
Hiroya Takeuchi
Masayuki Watanabe
Yuichiro Doki
Publication date
20-01-2023
Publisher
Springer Nature Singapore
Published in
Esophagus / Issue 3/2023
Print ISSN: 1612-9059
Electronic ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-022-00980-z

Other articles of this Issue 3/2023

Esophagus 3/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.